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■ CLINICAL COMMENTARY:
Respect the accepted inclusion and
exclusion criteria for using thrombolytics
Acute ischemic stroke has always posed the
dilemma of giving treatment that may be either
beneficial or harmful. Now the stakes of suc-
cess or failure are dramatically higher. Family
physicians must be knowledgeable about treat-
ment options, as the 3-hour window for using
rtPA after symptom onset is a diagnostic and
logistic challenge for physicians and staff. 
Our radiology colleagues help by using the
unenhanced head CT to exclude lesions that
mimic ischemic infarct and to confirm that true
stroke victims do not have identifiable infarc-
tion greater than one third of the middle cere-
bral artery territory. Clinicians involved in the
rtPA decision must know and respect fully and
without deviation the accepted inclusion and
exclusion criteria for using thrombolytics for
acute ischemic stroke, to promote recovery and
minimize death and disability due to intracra-
nial hemorrhage.
John Richmond, MD, University of Texas Southwestern
Family Practice Residency Program, Dallas
Is methylphenidate useful 
for treating adolescents 
with ADHD?
■ EVIDENCE-BASED ANSWER
Methylphenidate (Ritalin) is effective in the short-
term treatment of attention deficit/hyperactivity
disorder (ADHD) (strength of recommendation
[SOR]: A, multiple randomized control trials).
Though the immediate-release preparation is
the best studied of methylphenidate formulations,
extended-release methylphenidate (Concerta) has
similar benefits, with a dosing regimen that may
better suit an adolescent lifestyle (SOR: B, based
on extrapolation of 1 randomized controlled trial
and expert opinion).
■ EVIDENCE SUMMARY
The subjects of most ADHD medication studies
have been school-age children. Most children
with ADHD will have symptoms persisting into
teenage years, and methylphenidate has been
increasingly prescribed for them.1,2 Various 
systematic reviews and meta-analyses have
demonstrated the effectiveness of short-term
methylphenidate in the treatment of adolescents
with ADHD.3–5 Most participants in these studies
are males aged <13 years. Therefore, any conclu-
sions about the effectiveness of methylphenidate
in older adolescents must be inferred.
The most comprehensive systematic review
found 8 well-controlled crossover trials with an
average sample size of 24.8 (range, 9–48).6 The
average duration of the studies was 6 weeks.
The majority of the participants were white
males with a mean age of 13 years. Each study
showed statistically significant improvement
from treatment with methylphenidate. Average
effect sizes were calculated for 3 domains:
ADHD symptoms (0.94), social behavior (1.06),
and academic performance (1.25). Effect sizes
were calculated using a modified Cohen’s d,
which is the difference between the treated and
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untreated means divided by the standard devia-
tion in the untreated condition. It is difficult to
translate these changes in effect size into clini-
cally meaningful outcome measures, although
one rule of thumb estimates an effect size of 0.8
is moderate to large. 
Of the 3 studies that reported the proportion
of subjects with clinically significant improve-
ment, the modal result was about one half show-
ings improvement with methylphenidate. Of trials
assessing dosing levels, <50% found significant
differences between “low” and “high” doses.
However, the researchers did not give their defini-
tion of low and high doses. Also, diminishing clin-
ical improvement was noted with higher
methylphenidate doses. 
A single study on the once-daily stimulant
preparation, extended-release methylphenidate,
shows statistically significant improvement in
adolescent ADHD.7 In this multicenter, random-
ized, double-blind, placebo-controlled trial of 177
adolescents, subjects were given placebo (n=87)
or extended-release methylphenidate (n=90) at
titrated doses from 18 mg/d to 72 mg/d.
Following a subsequent 2-week randomization
phase, clinical investigators found extended-
release methylphenidate significantly superior to
placebo (P=.001) on the ADHD scale. Subjects
also rated it significantly superior to placebo
(P=.001) on the Conners-Wells’ Self-Report
Scale. Mean dose and average age were not
reported. This study has been presented as an
abstract and is not yet published.
■ RECOMMENDATIONS FROM OTHERS
The American Academy of Child and Adolescent
Psychiatry (AACAP) supports the prescribing of
methylphenidate in adolescents with ADHD.8
Given the unique psychosocial, environmental, and
scheduling challenges of adolescence, the AACAP
mentions extended-release methyl-phenidate as
“well-suited for treatment of adolescents.” 
Timothy F. Mott, MD, Navy Hospital Pensacola Family
Practice Residency, Pensacola, Fla; Laura Leach, MLIS,
Carolinas Healthcare System, Charlotte AHEC, Charlotte, NC
■ CLINICAL COMMENTARY:
Patients with childhood ADHD usually
benefit from continuing their medication
Adolescents must face the challenge of becom-
ing more organized and independent to be suc-
cessful in middle school and high school. Those
with childhood ADHD may have a particularly
difficult transition, and will usually benefit from
continuing to take their stimulants. Some ado-
lescents, who were not previously identified as
having ADHD, may declare themselves at this
age due to school performance issues. Careful
evaluation and treatment of these patients will
contribute to their success. 
Physicians should use the lowest effective
dose of methylphenidate, as the studies seem to
indicate that higher dosages do not improve per-
formance in adolescents. Teens often prefer
long-acting preparations, which obviate the
need to take medication at school. The studies
reviewed do not define long-term academic or
vocational success, which is a more important
outcome than symptom control for adolescents. 
Lisa Johnson, MD, Providence St. Peter’s Family
Practice Residency, Olympia, Wash
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■ EVIDENCE SUMMARY
No studies of inhaled beta-agonists have been con-
ducted with patients who have an explicit diagno-
sis of acute cough due to URI. While some clini-
cians feel a distinction between URI and acute
bronchitis should be made, there is significant
overlap between these diagnoses in clinical prac-
tice, as well as in the available studies. 
A systematic review looking at beta-agonists
for acute bronchitis included the clinical diag-
noses of both acute bronchitis and acute cough
because a standard definition of bronchitis is
lacking.1 Only two trials in this review examined
inhaled beta-agonists. When results from these
trials were combined for the outcome of produc-
tive cough at 7 days, inhaled beta-agonists
showed no benefit. However, the authors note
that details of the individual trials may help to
clarify the effect of inhaled beta-agonists.
One trial, a randomized controlled trial of
adult patients with acute bronchitis in 2 com-
munity-based family practices, compared 23
patients receiving albuterolin a multidose
inhaler (MDI) with 23 patients receiving place-
bo inhaler.2 Patients were also randomized to
receive erythromycin or placebo tablets.
Patients with pneumonia or a history of asthma
or chronic obstructive pulmonary disease
(COPD) were excluded. At 7 days, 61% of
patients in the albuterol group reported cough
compared with 91% in the control group (P=.02,
NNT=3). No statistically significant difference
was seen in productive cough or night cough.
Smokers responded to inhaled albuterol similar-
ly to nonsmokers. Erythromycin had no effect
on cough and side effects were similar among
all groups.
The other trial was a randomized controlled
trial of 80 adults with cough due to acute respi-
ratory infection; it compared fenoterol aerosol 4
times daily with placebo.3 Inhaled fenoterol is
not available in the US but is similar to
albuterol. This study showed no difference in
cough at 7 days (relative risk [RR]=0.83; 95%
confidence interval [CI], 0.52–1.30). In a sub-
group analysis, however, smokers and those
wheezing on initial exam had lower overall
symptom scores when treated with fenoterol.
■ RECOMMENDATIONS FROM OTHERS
We were unable to find any guidelines on the
use of albuterol via MDI for cough from bron-
chitis or URIs. 
■ CLINICAL COMMENTARY:
Inhaled beta-agonists may aid symptoms;
other outcomes may not be improved
Even without a history of lung disease,
patients presenting with cough due to acute
respiratory illness and with evidence of air-
flow obstruction (wheezing) appear to receive
symptom relief from inhaled beta-agonists.
Smokers may be another subgroup who bene-
fit from treatment. However, important
patient-oriented outcomes (such as reduced
need for over-the-counter medicines, general
well being, and return to work) do not
improve. If using inhaled albuterol to treat
acute cough in practice, one must also con-
sider the financial costs and adverse effects
associated with treatment.
Mary Maniscalco Stephens, MD, MPH, East
Tennessee State University, Johnson City, TN;
Joan Nashelsky, MLS, Family Practice Inquiries Network,
Inc, Iowa City, IA
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With beta-agonists, outcomes such
as need for OTC medications and
return to work do not improve
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